ClinicalTrials.gg
Not yet recruitingNCT07129239HEIRLOOMUpdated Aug 19, 2025

High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)

A Phase 3 interventional study of Maintenance in Wet Age-related Macular Degeneration (wAMD), sponsored by Clinique de Retine de l'est. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Clinique de Retine de l'est · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Macular Degeneration with a site in Canada — 11 open to participants now, 16 under way, 7 of them phase 3. Macular Degeneration · Canada.

Planned enrollment
38th of 77
180 · median 180
Started
2025
with 6 others
Phase 3
28 of 94
3 open now
Primary completion
2027-02
later than 5 of 15 live
Registered
92nd of 94
by date

Among the 94 studies in Macular Degeneration with a site in Canada, this one is the 38th largest by planned enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2025, is one of 28 in phase 3, reaches primary completion later than 5 of the 15 other live ones, and was the 92nd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

11 of the 94 studies in Macular Degeneration with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Macular Degeneration with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).

EYLEA® HD is approved by Health Canada has been tested in large clinical trials involving thousands of patients around the world and has been shown effective in the treatment of wAMD. The treatment regimen used in these trials involved 3 initial monthly injections of EYLEA® HD followed by an extension of the treatment interval on the 4th visit. This was necessary since all patients in this study did not previously have treatment injections for wAMD.

Currently there is not enough information on the best treatment regimen to use for patients that are switched to EYLEA® HD from EYLEA®.

Health Canada currently recommends that EYLEA® HD is administered every month for the first 3 doses, followed by a treatment every 8 to 16 weeks.

A total of 180 patients >18 years of age will participate in this study, which will be conducted at the Clinique de Retine de l'Est in Montreal, Quebec, Canada.

03

Conditions studied

  • Wet Age-related Macular Degeneration (wAMD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over the age of 18
  • Patients with neovascular AMD
  • Patients who have received aflibercept 2mg for a minimum of 3 loading injections plus 2 maintenance injections.
  • Can include 1 or 2 eyes per patient if one or both meet study criteria.

Exclusion criteria

Exclusion Criteria:

  • Patients with other maculopathy, including but not limited to:
  • Polypoidal choroidal vasculopathy
  • Macular dystrophies (ie. Pattern dystrophy, central areolar etc.)
  • Toxic/drug induced maculopathies
  • Disciform scar
  • Subfoveal atrophy
  • Previous Photodynamic Therapy (PDT) or focal laser
  • Is currently enrolled in another clinical study or observational study
  • Active use of a different agent in the fellow eye, to avoid cross-over effects of anti Vascular Endothelial Growth Factor (VEGF) administration to the fellow eye
  • If the patient is pregnant
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • No intervention
    Loading interval group

    patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and receive injections every month for the first 3 months followed by an extension (or increase in dosing interval) of therapy based on clinical response. This is the "on label" treatment regimen approved by Health Canada.

  • Experimental
    Maintenance interval group

    patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and maintain the current treatment interval that they had with EYLEA® (aflibercept 2mg), followed by an extension of therapy (or increase in treatment dosing interval) based on clinical response. This is the "off-label" treatment regimen that we are testing to see if it is as effective and involves less treatment burden.

    Other: Maintenance

Interventions

  • OtherMaintenance

    Patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and maintain the current treatment interval that they had with EYLEA® (aflibercept 2mg), followed by an extension of therapy (or increase in treatment dosing interval) based on clinical response

06

What researchers measure

Primary outcomes

  1. Central Retinal Thickness (CRT)

    The primary endpoint will derived from Optical Coherence Tomography (OCT), in µm and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).

    Time frame: 6 and 12 month

Secondary outcomes

  1. Visual Acuity

    Visual acuity measured by the Snellen method and then converted to Early Treatment Diabetic Retinopathy Study (EDTRS) letters. Change in visual acuity will be assessed at 6 and 12 months compared to baseline.

    Time frame: 6 and 12 month

  2. Number of injections

    duration between last injection at 6 months and 12 months from date of the switch measured

    Time frame: 6 and 12 month

  3. Adverse events

    Will be reported at 6 and 12 months from date of the switch measured by frequency of events (numerical), as well as descriptive for what type of adverse event.

    Time frame: 6 and 12 month

  4. Presence of Subretinal Fluid (Yes/No)

    This measure will be derived from Optical Coherence Tomography (OCT), and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).

    Time frame: 6 months and 12 months

  5. Presence of Intraretinal Fluid (Yes/No)

    This measure will be derived from Optical Coherence Tomography (OCT), and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).

    Time frame: 6 months and 12 months

  6. Pigment Epithelial Detachment (PED) Type

    Morphology and type of PED will be derived from Optical Coherence Tomography (OCT), and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).

    Time frame: 6 months and 12 months

  7. Pigment Epithelial Detachment (PED) Height

    This outcome measure will be derived from Optical Coherence Tomography (OCT), measured in um, and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).

    Time frame: 6 months and 12 months

07

Study locations

1 site
  • Clinique de Retine de L'Est
    Montreal, Quebec H1Y0E2, Canada
    • Cynthia Lacasse · Contactclacasse.retinedelest@gmail.com · 5143205045
    • Andrei Szigiato, Docteur · Principal investigator
    • Cynthia Qian, doctor · Sub investigator
    • Sebastien olivier, doctor · Sub investigator
    • Flavio Rezende, doctor · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Feb 2027, 18 months later.

Of 83 phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 35. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Aug 19, 2025
StartEst.
Aug 20, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07129239
Lead sponsor
Clinique de Retine de l'est
Collaborators
Bayer
Responsible party
Dr. Andrei Szigiato (Principal Investigator, Clinique de Retine de l'est) — Principal investigator
First posted
Aug 19, 2025
Start date
Aug 20, 2025 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 19, 2025

Study contacts

Cynthia lacasse
Contact
clacasse.retinedelest@gmail.com
5143205045
Andrei Szigiato, Docteur
principal investigator · Clinique de Retine de l'est

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion